This trial will assess the long-term safety and effectiveness of the drug Deucravacitinib in people who have already taken it for Crohn's disease or Ulcerative Colitis.
13 Primary · 0 Secondary · Reporting Duration: Up to Week 292
Experimental Treatment
300 Total Participants · 2 Treatment Groups
Primary Treatment: Deucravacitinib · No Placebo Group · Phase 2
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: